Levocetirizine: a review of its use in the management of allergic rhinitis and skin allergies.


:Levocetirizine (Xyzal) is a selective, potent, oral histamine H(1) receptor antagonist of the latest generation that is licensed for the symptomatic treatment of allergic rhinitis (including persistent allergic rhinitis [PER]) and chronic idiopathic urticaria (CIU). Large, well designed trials indicate that levocetirizine is effective and generally well tolerated in the treatment of allergic rhinitis and CIU. Its pharmacological profile offers many positive aspects: a rapid onset and long duration of antihistaminic effect; rapid absorption and high bioavailability; a low potential for drug interactions; a low volume of distribution; and a lack of effect on cognition, psychomotor function and the cardiovascular system. Allergen challenge chamber studies suggest that levocetirizine has better efficacy than desloratadine, loratadine or fexofenadine. Well controlled, long-term studies with other later-generation H(1) receptor antagonists are required to fully define its clinical profile relative to other agents in this class. Overall, levocetirizine is a valuable addition to the oral H(1) receptor antagonists available for the treatment of allergic rhinitis and as first-line therapy in patients with CIU.






Hair PI,Scott LJ




Has Abstract


2006-01-01 00:00:00
















  • Cardioprotective mechanisms of ACE inhibition. The angiotensin II-nitric oxide balance.

    abstract::The current challenge facing clinicians is to develop pharmacotherapies that move beyond the treatment of symptoms towards a new agenda in cardiovascular therapeutics that includes interventions to actually prevent the development of end-stage coronary heart disease. The development of new strategies to alter the natu...


    pub_type: 杂志文章,评审


    authors: Gibbons GH

    更新日期:1997-01-01 00:00:00

  • [Properties and features of nabumetone].

    abstract::Nabumetone is a nonsteroidal anti-inflammatory drug (NSAID) of the 2,6-disubstituted naphthylalkanone class. It is a prodrug metabolised to an active metabolite, 6-methoxy-2-naphthylacetic acid (6-MNA), which preferentially inhibits cyclo-oxygenase-2 (COX-2) and has both anti-inflammatory and analgesic properties. The...


    pub_type: 杂志文章,评审


    authors: Davies NM,McLachlan AJ

    更新日期:2000-01-01 00:00:00

  • Budesonide MMX(®): a review of its use in patients with mild to moderate ulcerative colitis.

    abstract::Budesonide MMX(®) (Cortiment(®); Uceris(®)) is a novel once-daily oral formulation of budesonide using Multi Matrix (MMX(®)) colonic delivery technology to permit the release of budesonide at a controlled rate throughout the colon. It is available in the USA for the induction of remission in patients with active, mild...


    pub_type: 杂志文章,评审


    authors: Hoy SM

    更新日期:2015-05-01 00:00:00

  • The Unique Pharmacological and Pharmacokinetic Profile of Teneligliptin: Implications for Clinical Practice.

    abstract::Teneligliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that was approved for the treatment of type 2 diabetes mellitus (T2DM) in Japan and Korea and is being researched in several countries. Teneligliptin is a potent, selective, and long-lasting DPP-4 inhibitor with a t½ of approximately 24 h and unique pharmacok...


    pub_type: 杂志文章,评审


    authors: Ceriello A,De Nigris V,Iijima H,Matsui T,Gouda M

    更新日期:2019-05-01 00:00:00

  • The Treatment of Advanced Thyroid Cancer in the Age of Novel Targeted Therapies.

    abstract::Until recently, patients with advanced thyroid cancers had limited options for systemic treatment. With the introduction of tyrosine kinase inhibitors (TKIs) as a promising new class of targeted therapies for thyroid cancer, suddenly patients with advanced disease were given new options to extend survival. Guidelines ...


    pub_type: 杂志文章


    authors: Lirov R,Worden FP,Cohen MS

    更新日期:2017-05-01 00:00:00

  • Lumasiran: First Approval.

    abstract::Lumasiran (Oxlumo™) is a subcutaneously administered small interfering RNA (siRNA) targeting the mRNA for hydroxyacid oxidase 1 gene (HAO1; encodes glycolate oxidase) and was developed by Alnylam Pharmaceuticals for the treatment of primary hyperoxaluria type 1 (PH1). By silencing the gene encoding glycolate oxidase, ...


    pub_type: 杂志文章,评审


    authors: Scott LJ,Keam SJ

    更新日期:2021-01-06 00:00:00

  • Targeting ROS1 Rearrangements in Non-small Cell Lung Cancer: Crizotinib and Newer Generation Tyrosine Kinase Inhibitors.

    abstract::ROS1 gene rearrangements exist in 1-2% of non-small cell lung cancers, typically occurring in younger, never or light smokers with adenocarcinoma. ROS1 gene fusions are potent oncogenic drivers, the presence of which results in the susceptibility of tumours to ROS1-targeted therapy. Crizotinib was the first tyrosine k...


    pub_type: 杂志文章,评审


    authors: Morris TA,Khoo C,Solomon BJ

    更新日期:2019-08-01 00:00:00

  • Inhibitory effects of nedocromil sodium on the in vitro induced migration and leukotriene formation of human granulocytes.

    abstract::Inflammatory cells, such as neutrophils and eosinophils, are thought to actively contribute to the pathogenesis of asthma since they infiltrate into the lung tissue and may be activated locally to release bronchoconstrictor mediators. In this study we provide evidence that nedocromil sodium is capable of effectively i...


    pub_type: 杂志文章


    authors: Bruijnzeel PL,Warringa RA,Kok PT,Hamelink ML,Kreukniet J

    更新日期:1989-01-01 00:00:00

  • The coming era of quadrivalent human influenza vaccines: who will benefit?

    abstract::Influenza vaccines form the mainstay of public health and personal protection against infection with seasonal influenza viruses. These vaccines are designed to protect people against infection with the currently circulating influenza viruses. Since the late 1970s, this has required the use of a trivalent vaccine consi...


    pub_type: 杂志文章


    authors: Barr IG,Jelley LL

    更新日期:2012-12-03 00:00:00

  • Emicizumab: A Review in Haemophilia A.

    abstract::Emicizumab (Hemlibra®), a recombinant, humanized, bispecific monoclonal antibody, restores the function of missing activated factor VIII (FVIII) by bridging FIXa and FX to facilitate effective haemostasis in patients with haemophilia A. Subcutaneous emicizumab is approved in several countries, including in the USA and...


    pub_type: 杂志文章,评审


    authors: Blair HA

    更新日期:2019-10-01 00:00:00

  • Management of insomnia in patients with chronic obstructive pulmonary disease.

    abstract::Chronic obstructive pulmonary disease (COPD) is a common medical disorder, which causes considerable morbidity and mortality. Given the chronic and symptomatic nature of the disease, the patient is often seen in the physician's office with complaints of dyspnea. However, more than 50% of COPD patients also have sleep ...


    pub_type: 杂志文章,评审


    authors: George CF,Bayliff CD

    更新日期:2003-01-01 00:00:00

  • [Review of current pharmacologic treatment of pain].

    abstract::Pain is the main reason prompting patients to consult their physicians. In acute conditions, pain has a very particular significance as a warning sign, enabling the physician to attempt a diagnosis. Nevertheless, its detrimental effect upon the individual (even in the case of acute pain) and its cost to society are no...


    pub_type: 杂志文章,评审


    authors: Brasseur L

    更新日期:1997-01-01 00:00:00

  • Advanced-stage follicular lymphoma in the rituximab era: when should patients receive anthracycline-based chemotherapy?

    abstract::Follicular lymphoma (FL), the most common subtype of indolent lymphoma, is usually diagnosed at an advanced stage (III-IV), although patients are often asymptomatic. Traditionally, a palliative approach to management has been taken, cycling through watchful waiting, radiotherapy, oral alkylating agents and, eventually...


    pub_type: 杂志文章


    authors: Pettengell R

    更新日期:2009-01-01 00:00:00

  • Quinidine and digoxin. An important interaction.

    abstract::An increase in serum digoxin concentration occurs in 90% of patients given quinidine. On average, the serum digoxin doubles during treatment with therapeutic doses of quinidine. Almost every patient treated with quinidine will have a decrease in the renal clearance of digoxin and many will have a decrease in the volum...


    pub_type: 杂志文章,评审


    authors: Bigger JT Jr,Leahey EB Jr

    更新日期:1982-09-01 00:00:00

  • Protective effects of calcium antagonists against ischaemia and reperfusion damage.

    abstract::The most positive results in this area have been those of the second Danish Study Group on Verapamil in Myocardial Infarction (1990) which assessed the benefit of treatment with verapamil from the second week after myocardial infarction. Verapamil produced a significant reduction in both mortality and reinfarction rat...


    pub_type: 杂志文章,评审


    authors: Ferrari R,Visioli O

    更新日期:1991-01-01 00:00:00

  • Immunotherapy Against Gliomas: is the Breakthrough Near?

    abstract::Immunotherapeutic approaches have been, and continue to be, aggressively investigated in the treatment of infiltrating gliomas. While the results of late-phase clinical studies have been disappointing in this disease space thus far, the success of immunotherapies in other malignancies as well as the incremental gains ...


    pub_type: 杂志文章,评审


    authors: Lukas RV,Wainwright DA,Horbinski CM,Iwamoto FM,Sonabend AM

    更新日期:2019-11-01 00:00:00

  • The cost of treating systemic fungal infections.

    abstract::The increasing incidence of systemic fungal infections and rising medical costs have highlighted the need for an economic appraisal of antifungal agents to determine the most cost-effective therapeutic option. Cost savings derived from the prophylactic or empirical use of antifungal agents have been difficult to estim...


    pub_type: 杂志文章,评审


    authors: van Gool R

    更新日期:2001-01-01 00:00:00

  • Bezafibrate. An update of its pharmacology and use in the management of dyslipidaemia.

    abstract::The lipid-modifying profile of bezafibrate is characterised by marked decreases in elevated triglyceride levels, increases in high density lipoprotein (HDL) cholesterol levels and decreases in total and low density lipoprotein (LDL) cholesterol levels. Bezafibrate also reduces elevated levels of lipoprotein(a) [Lp(a)]...


    pub_type: 杂志文章,评审


    authors: Goa KL,Barradell LB,Plosker GL

    更新日期:1996-11-01 00:00:00

  • Cholinesterase inhibitors for Alzheimer's disease.

    abstract::Alzheimer's disease (AD) is the most common age-related neurodegenerative disease and has become an urgent public health problem in most areas of the world. Substantial progress has been made in understanding the basic neurobiology of AD and, as a result, new drugs for its treatment have become available. Cholinestera...


    pub_type: 杂志文章,评审


    authors: Grutzendler J,Morris JC

    更新日期:2001-01-01 00:00:00

  • Iloprost. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in peripheral vascular disease, myocardial ischaemia and extracorporeal circulation procedures.

    abstract::Iloprost is an analogue of epoprostenol (prostacyclin; PGI2; a potent but short-lived prostanoid mainly produced in the vascular endothelium) and mimics the pharmacodynamic properties of this compound, namely: inhibition of platelet aggregation, vasodilatation and, as yet ill-defined, cytoprotection. Improved metaboli...


    pub_type: 杂志文章,评审


    authors: Grant SM,Goa KL

    更新日期:1992-06-01 00:00:00

  • Dexamethasone in adults with community-acquired bacterial meningitis.

    abstract::Bacterial meningitis in adults is a severe disease with high fatality and morbidity rates. Experimental studies have shown that the inflammatory response in the subarachnoid space is associated with an unfavourable outcome. In these experiments, corticosteroids, and in particular dexamethasone, were able to reduce the...


    pub_type: 杂志文章,评审


    authors: van de Beek D,de Gans J

    更新日期:2006-01-01 00:00:00

  • Current and Emerging Drug Therapies for Connective Tissue Disease-Interstitial Lung Disease (CTD-ILD).

    abstract::Interstitial lung disease (ILD) can be associated with all connective tissue diseases and is an important cause of morbidity and mortality. The management of connective tissue disease-interstitial lung disease (CTD-ILD) is challenging due substantial heterogeneity in disease behaviour and paucity of controlled clinica...


    pub_type: 杂志文章,评审


    authors: Jee AS,Corte TJ

    更新日期:2019-09-01 00:00:00

  • Community-associated meticillin-resistant Staphylococcus aureus infections: epidemiology, recognition and management.

    abstract::Meticillin-resistant Staphylococcus aureus (MRSA) is an important cause of infection, particularly in hospitalized patients and those with significant healthcare exposure. In recent years, epidemic community-associated MRSA (CA-MRSA) infections occurring in patients without healthcare risk factors have become more fre...


    pub_type: 杂志文章,评审


    authors: Patel M

    更新日期:2009-01-01 00:00:00

  • NSAIDs and gastrointestinal cancer prevention.

    abstract::Numerous studies report the relationship between aspirin and other nonsteroidal anti-inflammatories (NSAIDs) and cancer incidence, in particular for colorectal cancer. This paper systematically reviews the evidence of the effect of aspirin and other NSAIDs on the primary prevention of colorectal and other gastrointest...


    pub_type: 杂志文章,评审


    authors: Jolly K,Cheng KK,Langman MJ

    更新日期:2002-01-01 00:00:00

  • The sore throat. When to investigate and when to prescribe.

    abstract::Sore throats are most commonly due to infections, many of which are viral and do not require specific treatment. Symptoms and signs of the common cold, influenza or croup, the occurrence of conjunctivitis in some adenoviral infections, generalised lymphadenopathy and splenomegaly in glandular fever or the presence of ...


    pub_type: 杂志文章,评审


    authors: Lang SD,Singh K

    更新日期:1990-12-01 00:00:00

  • Various administration forms of nitrates and their possibilities.

    abstract::This article reviews the development and pharmacokinetics of a number of new dosage formulations (e.g. transdermal patches and buccal tablets) and new active substances (e.g. isosorbide 5-mononitrate) which have recently been introduced to overcome some of the problems inherent in conventional formulations of organic ...


    pub_type: 杂志文章,评审


    authors: Jonsson UE

    更新日期:1987-01-01 00:00:00

  • Certolizumab pegol: a review of its use in the management of rheumatoid arthritis.

    abstract::Certolizumab pegol (Cimzia(®)) is a recombinant, polyethylene glycolylated, antigen-binding fragment of a humanized monoclonal antibody that selectively targets and neutralizes tumour necrosis factor (TNF)-α. The drug is indicated for subcutaneous use every 2 or 4 weeks (q2w or q4w) for the treatment of adults with mo...


    pub_type: 杂志文章,评审


    authors: Deeks ED

    更新日期:2013-01-01 00:00:00

  • Empagliflozin/Linagliptin: A Review in Type 2 Diabetes.

    abstract::Empagliflozin/linagliptin (Glyxambi(®)) is a once-daily sodium glucose co-transporter type 2 (SGLT2) inhibitor and dipeptidyl peptidase (DPP)-4 inhibitor fixed-dose combination product that is approved in the USA as an adjunct to diet and exercise in adults with type 2 diabetes (T2D) when treatment with both empaglifl...


    pub_type: 杂志文章,评审


    authors: Kim ES,Deeks ED

    更新日期:2015-09-01 00:00:00

  • Treatment options for sleep apnoea.

    abstract::Sleep apnoea (SA) is a common sleep disorder affecting 4 to 25% of the adult population. The most common form, obstructive SA, is characterised by recurrent upper airway obstruction during sleep associated with sleep disruption and hypoxaemia. There is increasing evidence that SA leads to impaired vigilance, quality o...


    pub_type: 杂志文章,评审


    authors: Grunstein RR,Hedner J,Grote L

    更新日期:2001-01-01 00:00:00

  • Microbiological evaluation of cefpodoxime proxetil.

    abstract::Cefpodoxime, the active de-esterified molecule of the orally absorbable cephalosporin cefpodoxime proxetil, inhibits streptococci, Neisseria spp., and most Enterobacteriaceae, with MIC50 and/or MIC90 values of less than or equal to 2 mg/L; with regard to the latter family of bacteria, the MIC50 and/or MIC90 values of ...


    pub_type: 杂志文章


    authors: Wiedemann B,Luhmer E,Zühlsdorf MT

    更新日期:1991-01-01 00:00:00